Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Endothelin-1 and human platelets.

I Anita Jagroop1, Stella S Daskalopoulou, Dimitri P Mikhailidis

  • 1Department of Clinical Biochemistry, Royal Free University College Medical School, University of London, UK.

Current Vascular Pharmacology
|October 27, 2005
PubMed
Summary

Conflicting evidence exists on endothelin-1 (ET-1) effects on platelets. This review examines studies on ET-1 and human platelets, considering its role in vascular diseases and potential therapeutic antagonism.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The role of fibrate treatment in dyslipidemia: an overview.

Current pharmaceutical design·2013
Same author

Ezetimibe therapy for dyslipidemia: an update.

Current pharmaceutical design·2013
Same author

Colesevelam: a new and improved bile acid sequestrant?

Current pharmaceutical design·2013
Same author

Hydrochlorothiazide vs. chlorthalidone as the optimal diuretic for the management of hypertension.

Current pharmaceutical design·2013
Same author

PCSK9 inhibition - a novel mechanism to treat lipid disorders?

Current pharmaceutical design·2013
Same author

Combined dyslipidemia: should the focus be LDL cholesterol or atherogenic dyslipidemia?

Current pharmaceutical design·2013

Area of Science:

  • Cardiovascular Biology
  • Pharmacology
  • Hematology

Background:

  • Endothelin-1 (ET-1) has complex and debated effects on human platelet activation.
  • Conflicting research findings suggest potential involvement of ET-1 receptors (ET(A) and ET(B)) in these varied responses.
  • ET-1 antagonism is a potential therapeutic strategy for vascular disorders, with bosentan being the sole approved dual ET-1 antagonist.

Purpose of the Study:

  • To review existing literature on the effects of endothelin-1 on human platelets.
  • To explore the potential role of ET-1 receptor interactions in observed platelet responses.
  • To discuss the implications of ET-1 antagonism in vascular diseases and its potential impact on platelets.

Main Methods:

  • Literature review of studies investigating endothelin-1's impact on human platelets.

Related Experiment Videos

  • Analysis of research examining ET-1 receptor subtypes (ET(A) and ET(B)) and their function in platelets.
  • Consideration of clinical data on ET-1 antagonists, such as bosentan, in vascular disease management.

    • Main Results:

    • Evidence on ET-1's effect on platelets is inconsistent, with studies reporting activation, inhibition, or no effect.
    • Complex interactions between platelet ET(A) and ET(B) receptors are hypothesized to explain the conflicting results.
    • The specific effects of dual ET-1 antagonists like bosentan on platelets require further investigation.

    Conclusions:

    • The precise role of endothelin-1 in human platelet function remains unclear due to contradictory findings.
    • Understanding ET-1 receptor signaling in platelets is crucial for developing targeted therapies.
    • Further research is needed to elucidate the platelet-specific mechanisms of ET-1 and its antagonists in vascular disease contexts.